Cosmo N.V.
CMHC.SW
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.07B
Close$
$26.64
45.6% downside
Current Fair Value
45.6% downsideOvervalued by 45.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.07 Billion |
|---|---|
| Enterprise Value | $1.04 Billion |
| Dividend Yield | $1.95 (3.80%) |
| Earnings per Share | $-0.23 |
| Beta | 1.64 |
| Outstanding Shares | 17,042,708 |
Return
| Return on Equity | 8.62% |
|---|---|
| Return on Assets | 7.03% |
| Return on Invested Capital | 7.65% |
Valuation & Multiples
| P/E Ratio | -145.36 |
|---|---|
| PEG | -106.57 |
| Price to Sales | 3.06 |
| Price to Book Ratio | 1.48 |
| Enterprise Value to Revenue | 3.66 |
| Enterprise Value to EBIT | 20.32 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
$22.79 M
Average shareholder expectationNext Earnings Call
Expected Date
March 24, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$50.87 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cosmo N.V.
324 employees
CEO: Giovanni di Napoli Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that...